154 related articles for article (PubMed ID: 36478321)
1. High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach.
Chu J; Min KW; Kim DH; Son BK; Kim HS; Jung US; Kwon MJ; Do SI
Breast Cancer; 2023 Mar; 30(2):259-270. PubMed ID: 36478321
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblasts Together with a Decline in CD8+ T Cells Predict a Worse Prognosis for Breast Cancer Patients.
Kim HS; Noh YK; Min KW; Kim DH; Kwon MJ; Pyo JS; Lee JY
Ann Surg Oncol; 2024 Mar; 31(3):2114-2126. PubMed ID: 38093168
[TBL] [Abstract][Full Text] [Related]
3. PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
Alfarsi LH; El Ansari R; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
BMC Cancer; 2020 May; 20(1):425. PubMed ID: 32410585
[TBL] [Abstract][Full Text] [Related]
4. High BMI1 Expression with Low CD8+ and CD4+ T Cell Activity Could Promote Breast Cancer Cell Survival: A Machine Learning Approach.
Chung Y; Min KW; Kim DH; Son BK; Do SI; Chae SW; Kwon MJ
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442383
[TBL] [Abstract][Full Text] [Related]
5. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
[TBL] [Abstract][Full Text] [Related]
6. Low CDKN1B Expression Associated with Reduced CD8+ T Lymphocytes Predicts Poor Outcome in Breast Cancer in a Machine Learning Analysis.
Kim HS; Noh YK; Min KW; Kim DH
J Pers Med; 2023 Dec; 14(1):. PubMed ID: 38248731
[TBL] [Abstract][Full Text] [Related]
7. JAK2 Loss Arising From Tumor-Spread-Through-Air-Spaces (STAS) Promotes Tumor Progression by Suppressing CD8+ T Cells in Lung Adenocarcinoma: A Machine Learning Approach.
Choi S; Kim HS; Min KW; Noh YK; Lee JY; Moon JY; Jung US; Kwon MJ; Kim DH; Son BK; Pyo JS; Ro SK
J Korean Med Sci; 2024 Jan; 39(2):e16. PubMed ID: 38225784
[TBL] [Abstract][Full Text] [Related]
8. High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
Kim HS; Kim MG; Min KW; Jung US; Kim DH
PLoS One; 2021; 16(5):e0252052. PubMed ID: 34038440
[TBL] [Abstract][Full Text] [Related]
9. High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.
Han MH; Min KW; Noh YK; Kim JM; Cheong JH; Ryu JI; Won YD; Koh SH; Myung JK; Park JY; Kwon MJ
Cancer Immunol Immunother; 2022 Dec; 71(12):3013-3027. PubMed ID: 35599254
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breast.
Choi EJ; Yun JA; Jabeen S; Jeon EK; Won HS; Ko YH; Kim SY
World J Surg Oncol; 2014 May; 12():137. PubMed ID: 24886289
[TBL] [Abstract][Full Text] [Related]
12. PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Dancau AM; Wuth L; Waschow M; Holst F; Krohn A; Choschzick M; Terracciano L; Politis S; Kurtz S; Lebeau A; Friedrichs K; Wencke K; Monni O; Simon R
Genes Chromosomes Cancer; 2010 Jan; 49(1):1-8. PubMed ID: 19787783
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
18. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
19. High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma.
Murata D; Mineharu Y; Arakawa Y; Liu B; Tanji M; Yamaguchi M; Fujimoto KI; Fukui N; Terada Y; Yokogawa R; Yamaguchi M; Minamiguchi S; Miyamoto S
J Neurosurg; 2018 Mar; 128(3):710-716. PubMed ID: 28474991
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
